1 Major Depressive Disorder: Executive Summary
1.1 MDD Therapeutics Market Will Grow to $7.9B by 2029
1.2 Key Players Will Struggle to Maintain Their Competitive Position
1.3 Better Efficacy and Rapid Onset of Action Are the Most Pressing Unmet Needs in the MDD Market
1.4 Novel Late-Stage Pipeline Drugs Will Be a Key Driver of Growth
1.5 What Do Physicians Think?

2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Reports

3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Classification
3.3 Prognosis
3.4 Quality of Life

4 Epidemiology
4.1 Disease Background
4.2 Risk Factors and Comorbidities
4.3 Global and Historical Trends
4.4 Forecast Methodology
4.4.1 Sources Used
4.4.2 Sources Not Used
4.4.3 Forecast Assumptions and Methods
4.4.4 Forecast Assumptions and Methods: 12-Month Total Prevalence of MDD
4.4.5 Forecast Assumptions and Methods: 12-Month Total Prevalence of MDD by Severity
4.5 Epidemiological Forecast for MDD (2019-2029)
4.5.1 12-Month Total Prevalent Cases of MDD
4.5.2 Age-Specific 12-Month Total Prevalence of MDD
4.5.3 Sex-Specific 12-Month Prevalent Cases of MDD
4.5.4 12-Month Total Prevalent Cases of MDD by Severity for Ages <18 Years
4.6 Discussion
4.6.1 Epidemiological Forecast Insight
4.6.2 Coronavirus Disease 2019 (COVID-19) Impact
4.6.3 Limitations of Analysis
4.6.4 Strengths of Analysis

5 Disease Management
5.1 Diagnosis and Treatment Overview
5.2 KOL Insights on Disease Management

6 Competitive Assessment
6.1 Overview

7 Unmet Needs and Opportunity Assessment
7.1 Overview
7.2 Rapid Onset of Action
7.3 New Therapies with Better Efficacy
7.4 Improved Safety Profiles
7.5 Management of Patient Outcome Expectations

8 R&D Strategies
8.1 Overview
8.1.1 Novel MOAs
8.1.2 Development of Adjunctive Therapies
8.1.3 Digital Therapeutics
8.1.4 Personalized Treatments/Biomarkers
8.2 Clinical Trials Design
8.2.1 Study Design
8.2.2 Endpoints
8.2.3 Placebo Response Rates

9 Pipeline Assessment
9.1 Overview
9.2 Promising Drugs in Clinical Development
9.3 Other Drugs in Development

10 Pipeline Valuation Analysis
10.1 Overview
10.2 Competitive Assessment

11 Current and Future Players
11.1 Overview
11.2 Deal-Making Trends

12 Market Outlook
12.1 Global Markets
12.1.1 Forecast
12.1.2 Drivers and Barriers - Global Issues
12.2 US
12.2.1 Forecast
12.2.2 Key Events
12.2.3 Drivers and Barriers
12.3 5EU
12.3.1 Forecast
12.3.2 Key Events
12.3.3 Drivers and Barriers
12.4 Japan
12.4.1 Forecast
12.4.2 Key Events
12.4.3 Drivers and Barriers
12.5 Canada
12.5.1 Forecast
12.5.2 Key Events
12.5.3 Drivers and Barriers

13 Appendix

List of Tables
Table 1: Major Depressive Disorder: Key Metrics in the 8MM
Table 2: DSM-V Criteria of Major Depressive Episode
Table 3: ICD-10 Criteria of Major Depressive Episode
Table 4: Subtypes of Major Depressive Episode
Table 5: Risk Factors and Comorbidities for MDD
Table 6: Treatment Guidelines for Major Depressive Disorder
Table 7: Drugs in Development for Major Depressive Disorder, 2021
Table 8: MDD Market - Global Drivers and Barriers, 2019-2029
Table 9: Key Events Impacting Sales for MDD in the US, 2019-2029
Table 10: MDD Market - Drivers and Barriers in the US, 2019-2029
Table 11: Key Events Impacting Sales for MDD in the 5EU, 2019-2029
Table 12: MDD Market - Drivers and Barriers in the 5EU, 2019-2029
Table 13: Key Events Impacting Sales for MDD in Japan, 2019-2029
Table 14: MDD Market - Drivers and Barriers in Japan, 2019-2029
Table 15: Key Events Impacting Sales for MDD in Canada, 2019-2029
Table 16: MDD Market - Drivers and Barriers in Canada, 2019-2029
Table 17: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures
Figure 1: Global Sales Forecast by Country for MDD in 2019 and 2029
Figure 2: Analysis of the Company Portfolio Gap in MDD During the Forecast Period
Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of MDD During the Forecast Period
Figure 4: Overview of Targets of Antidepressant Action on Noradrenergic and Serotonergic Neurons
Figure 5: 8MM, 12-Month Total Prevalence of MDD (%), Men and Women, Ages ?18 Years, 2019
Figure 6: 8MM, Sources Used and Not Used to Forecast the 12-Month Total Prevalent Cases of MDD
Figure 7: 8MM, Sources Used to Forecast the 12-Month Total Prevalent Cases of MDD, by Severity
Figure 8: 8MM, 12-Month Total Prevalent Cases of MDD, N, Both Sexes, Ages ?18 Years, 2019
Figure 9: 8MM, 12-Month Total Prevalent Cases of MDD by Age, N, Both Sexes, 2019
Figure 10: 8MM, 12-Month Total Prevalent Cases of MDD by Sex, N, Ages ?18 Years, 2019
Figure 11: 8MM, Total Prevalent Cases of MDD by Severity, N, Ages ?18 Years, 2019
Figure 12: Disease Management Model for MDD
Figure 13: MDD Treatment Algorithm
Figure 14: Unmet Needs and Opportunities in MDD
Figure 15: Overview of the Development Pipeline in Major Depressive Disorder
Figure 16: Key Late-Stage Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for MDD in the 8MM During the Forecast Period
Figure 17: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of MDD During the Forecast Period
Figure 18: Competitive Assessment of the Marketed and Pipeline Drug Monotherapies Benchmarked Against the Standard of Care (SOC), Lexapro
Figure 19: Competitive Assessment of the Marketed and Pipeline Drug Adjunctive Therapies Benchmarked Against the Standard of Care (SOC), Abilify
Figure 20: Analysis of the Company Portfolio Gap in MDD During the Forecast Period
Figure 21: Global (8MM) Sales Forecast by Country for MDD in 2019 and 2029
Figure 22: Global (8MM) Sales Forecast by Drug Class for MDD in 2019 and 2029
Figure 23: Sales Forecast by Class for MDD in the US in 2019 and 2029
Figure 24: 5EU Sales Forecast by Country for MDD in 2019 and 2029
Figure 25: 5EU Sales Forecast by Class for MDD in 2019 and 2029
Figure 26: Sales Forecast by Class for MDD in Japan in 2019 and 2029
Figure 27: Sales Forecast by Class for MDD in Canada in 2019 and 2029

Companies Mentioned
- Axsome Therapeutics
- Relmada Therapeutics
- AbbVie
- Lundbeck
- Takeda
- Otsuka
- Allergan
- Janssen
- Pfizer
- Sage Therapeutics
- Eli Lilly
- Intra-Cellular Therapies
- Biogen
- Luye Pharma
- GSK
- Merck
- AstraZeneca
- Bristol-Myers Squibb
- Click Therapeutics
- Kao Health
- Veeva Systems
- Fabre-Kramer Pharmaceuticals